½ÃÀ庸°í¼­
»óǰÄÚµå
1672653

µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ÀûÀÀÁõº°, Æ÷Àå À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°

Lyophilized Drugs Market, By Drug Class, By Indication, By Packaging Type, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀåÀº 2025³â¿¡ 3,710¾ï 9,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 6,831¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 9.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 3,710¾ï 9,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£: 2025-2032³â CAGR: 9.10% 2032³â °¡Ä¡ ¿¹Ãø 6,831¾ï 8,800¸¸ ´Þ·¯
µµÇ¥. 2025³â Áö¿ªº° µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå Á¡À¯À²(%)
Lyophilized Drugs Market-IMG1

¼¼°è µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â °ÍÀº ¾ÈÁ¤¼º Çâ»ó, Åõ¿© ¿ëÀ̼º, ¿î¼Û ºñ¿ë Àý°¨ µî ÀǾàǰ µ¿°á°ÇÁ¶¿Í °ü·ÃµÈ ´Ù¾çÇÑ ÀÌÁ¡ÀÔ´Ï´Ù. µ¿°á°ÇÁ¶´Â Á¦Á¦¿¡¼­ ¼öºÐÀ» Á¦°ÅÇÏ¿© ¹Ì»ý¹°ÀÇ ¹ø½ÄÀ» ¹æÁöÇϰí ÀǾàǰÀÇ À¯Åë±âÇÑÀ» ¿¬ÀåÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ³ÃÀå º¸°ü ¾øÀÌ ÀǾàǰÀ» º¸°ü ¹× ¿î¼ÛÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ Áõ°¡¿Í »õ·Î¿î ¾à¹°Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Á¦¾à»çÀÇ R&D ÅõÀÚ Áõ°¡¿¡ µû¶ó µ¿°á°ÇÁ¶ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä´Â ¿¹Ãø ±â°£ Áß Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀåÀº ³ëÀÎ Àα¸ Áõ°¡, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, º¸Á¸ ±â°£ÀÌ ±æ°í ¹Ì»ý¹° ¿À¿° À§ÇèÀÌ ³·´Ù´Â µ¿°á°ÇÁ¶ ÀǾàǰÀÇ ÀåÁ¡¿¡ ÈûÀÔ¾î ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ±×·¯³ª µ¿°á°ÇÁ¶ Àåºñ ¹× ½Ã¼ú°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ½ÅÈï ½ÃÀåÀº ÀÇ·á ÀÎÇÁ¶ó °³¼±°ú ÀÇ·á ÁöÃâ Áõ°¡·Î ÀÎÇØ ½ÃÀå ±â¾÷¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ º¸´Ù È¿À²ÀûÀÎ »õ·Î¿î µ¿°á°ÇÁ¶ ±â¼ú °³¹ß ¿¬±¸°¡ ÁøÇà ÁßÀ̸ç, ÀÌ´Â ¿¹Ãø ±â°£ Áß ¼¼°è ½ÃÀå È®´ëÀÇ ±âȸ¸¦ ´õ¿í âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀåÀÇ Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • °³¿ä
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±ÝÁ¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®

Á¦4Àå ¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ±¸»ó
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • Ç×°¨¿°
  • Ç×Á¾¾ç¾à
  • ÀÌ´¢Á¦
  • ÇÁ·ÎÅæÆßÇÁ ÀúÇØÁ¦
  • ¸¶ÃëÁ¦
  • Ç×ÀÀ°íÁ¦
  • NSAID
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå, Æ÷Àå À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • ¹ÙÀ̾Ë
  • ÁÖ»ç
  • īƮ¸®Áö

Á¦7Àå ¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå, ÀûÀÀÁõº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • Á¾¾çÇÐ
  • °¨¿°Áõ
  • ÀÚ°¡¸é¿ªÁúȯ
  • ¼ÒÈ­±â Áúȯ
  • ÇǺΠÁúȯ
  • È£Èí±âÁúȯ
  • ¾È°ú Áúȯ
  • È£¸£¸ó Àå¾Ö
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ µ¿°á°ÇÁ¶ ÀǾàǰ ½ÃÀå, Áö¿ªº°, 2020-2032³â, (10¾ï ´Þ·¯)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
      • °ÉÇÁÇù·ÂȸÀÇ
      • À̽º¶ó¿¤
      • ±âŸ Áßµ¿
    • ¾ÆÇÁ¸®Ä«
        • ºÏ¾ÆÇÁ¸®Ä«
        • Áß¾Ó¾ÆÇÁ¸®Ä«
        • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

    Á¦10Àå °æÀï ±¸µµ

    • ±â¾÷ °³¿ä
      • Pfizer Inc.
      • Novartis AG
      • Roche Holding AG
      • Johnson &Johnson
      • Sanofi SA
      • Amgen Inc.
      • AbbVie Inc.
      • Merck &Co., Inc.
      • Eli Lilly and Company
      • AstraZeneca PLC
      • Bristol Myers Squibb Company
      • GlaxoSmithKline plc
      • Gilead Sciences, Inc.
      • Biogen Inc.
      • Teva Pharmaceutical Industries Ltd.
      • Mylan NV
      • Celgene Corporation
      • Novo Nordisk A/S
      • Vertex Pharmaceuticals Incorporated
      • Takeda Pharmaceutical Company Limited

    Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

    • ¿î¸íÀÇ ¼ö·¹¹ÙÄû
    • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
    • COM(Coherent Opportunity Map)

    Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

    • Âü°í ¹®Çå
    • Á¶»ç ¹æ¹ý
    KSA 25.04.02

    Global Lyophilized Drugs Market is estimated to be valued at USD 371.09 Bn in 2025 and is expected to reach USD 683.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032.

    Report Coverage Report Details
    Base Year: 2024 Market Size in 2025: USD 371.09 Bn
    Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
    Forecast Period 2025 to 2032 CAGR: 9.10% 2032 Value Projection: USD 683.18 Bn
    Figure. Lyophilized Drugs Market Share (%), By Region 2025
    Lyophilized Drugs Market - IMG1

    The global lyophilized drugs market growth is driven by various advantages associated with lyophilization of drugs such as improved stability, ease of administration, and reduced transportation costs. Lyophilization or freeze-drying helps extend the shelf life of drugs by removing water from the formulations, thereby preventing the growth of microorganisms. It also enables storage and transportation of drugs without refrigeration. With the growing prevalence of chronic diseases and increasing R&D investments of pharmaceutical companies in novel drug delivery solutions, the demand for lyophilized drugs is expected to rise substantially during the forecast period.

    Market Dynamics:

    The global lyophilized drugs market is driven by the growing geriatric population, rising incidence of chronic diseases, and advantages of lyophilized drugs such as longer shelf life and lower risk of microbial contamination. However, high costs associated with lyophilization equipment and procedures are expected to restrain the market growth. On the other hand, emerging markets of Asia Pacific and Latin America are likely to offer lucrative opportunities for market players owing to improving healthcare infrastructure and increasing healthcare spending in these regions. Additionally, ongoing research for development of novel and more efficient lyophilization technologies will further create opportunities for the expansion of the global market during the forecast period.

    Key Features of the Study:

    • This report provides in-depth analysis of the global lyophilized drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
    • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
    • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
    • It profiles key players in the global lyophilized drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
    • Key companies covered as a part of this study include Pfizer Inc., Baxter International Inc., Jadavpur University, Merck & Co., Inc., and GlaxoSmithKline plc.
    • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
    • The global lyophilized drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
    • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lyophilized drugs market

    Detailed Segmentation-

    • By Drug Class
      • Anti-infective
      • Antineoplastic
      • Diuretics
      • Proton Pump Inhibitor
      • Anesthetic
      • Anticoagulant
      • NSAID's
      • Others
    • By Indication
      • Oncology
      • Infectious Disease
      • Autoimmune Disease
      • Gastrointestinal Disease
      • Dermatological Disorders
      • Respiratory Diseases
      • Ophthalmic Diseases
      • Hormonal Disorders
      • Others
    • By Packaging Type
      • Vial
      • Injection
      • Cartridge
    • By Distribution Channel
      • Hospital Pharmacy
      • Retail Pharmacy
      • Online Pharmacy
    • By Region:
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East
      • Africa
    • Company Profiles:
      • Pfizer Inc.
      • Novartis AG
      • Roche Holding AG
      • Johnson & Johnson
      • Sanofi S.A.
      • Amgen Inc.
      • AbbVie Inc.
      • Merck & Co., Inc.
      • Eli Lilly and Company
      • AstraZeneca PLC
      • Bristol Myers Squibb Company
      • GlaxoSmithKline plc
      • Gilead Sciences, Inc.
      • Biogen Inc.
      • Teva Pharmaceutical Industries Ltd.
      • Mylan N.V.
      • Celgene Corporation
      • Novo Nordisk A/S
      • Vertex Pharmaceuticals Incorporated
      • Takeda Pharmaceutical Company Limited

    Table of Contents

    1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations

    2. Market Purview

    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Indication
      • Market Snapshot, By Packaging Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)

    3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Acquisitions and Partnerships Scenario
    • Funding and Investments
    • PEST Analysis
    • Porter's Analysis

    4. Global Lyophilized Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

    • Overall Impact
    • Government Initiatives
    • COVID-19 Impact on the Market

    5. Global Lyophilized Drugs Market, By Drug Class, 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Anti-infective
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Antineoplastic
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Diuretics
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Proton Pump Inhibitor
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Anesthetic
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Anticoagulant
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • NSAID's
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    6. Global Lyophilized Drugs Market, By Packaging Type, 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Vial
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Injection
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Cartridge
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    7. Global Lyophilized Drugs Market, By Distribution Channel , 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Hospital Pharmacy
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Retail Pharmacy
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Online Pharmacy
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    8. Global Lyophilized Drugs Market, By Indication, 2020 - 2032, (USD Bn)

    • Overview
      • Market Share Analysis, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, 2021 - 2032
      • Segment Trends
    • Oncology
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Infectious Disease
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Autoimmune Disease
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Gastrointestinal Disease
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Dermatological Disorders
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Respiratory Diseases
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Ophthalmic Diseases
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Hormonal Disorders
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

    9. Global Lyophilized Drugs Market, By Region, 2020 - 2032, (USD Bn)

    • Introduction
      • Market Share Analysis, By Region, 2025 and 2032 (%)
      • Y-o-Y Growth Analysis, For Region, 2021-2032
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel2019 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
        • North Africa
        • Central Africa
        • South Africa

    10. Competitive Landscape

    • Company Profiles
      • Pfizer Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Novartis AG
      • Roche Holding AG
      • Johnson & Johnson
      • Sanofi S.A.
      • Amgen Inc.
      • AbbVie Inc.
      • Merck & Co., Inc.
      • Eli Lilly and Company
      • AstraZeneca PLC
      • Bristol Myers Squibb Company
      • GlaxoSmithKline plc
      • Gilead Sciences, Inc.
      • Biogen Inc.
      • Teva Pharmaceutical Industries Ltd.
      • Mylan N.V.
      • Celgene Corporation
      • Novo Nordisk A/S
      • Vertex Pharmaceuticals Incorporated
      • Takeda Pharmaceutical Company Limited

    11. Analyst Recommendations

    • Wheel of Fortune
    • Analyst View
    • Coherent Opportunity Map

    12. References and Research Methodology

    • References
    • Research Methodology
    • About Us and Sales Contact
  • ºñ±³¸®½ºÆ®
    0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
    »óǰ ºñ±³Çϱâ
    Àüü»èÁ¦